PriceTargets.com logo

Immuneering - IMRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.50
  • Forecasted Upside: 294.14%
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 2 Strong Buy Ratings
$4.44 As of 09/15/2026 05:00 PM ET
▲ +0.11 (2.54%)

This chart shows the closing price for IMRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Immuneering Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMRX

Analyst Price Target is $17.50
▲ +294.14% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Immuneering in the last 3 months. The average price target is $17.50, with a high forecast of $30.00 and a low forecast of $12.00. The average price target represents a 294.14% upside from the last price of $4.44.

This chart shows the closing price for IMRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Immuneering. This rating has held steady since July 2026, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/22/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/20/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/17/2026
  • 2 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/16/2026
  • 2 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/15/2026

Latest Recommendations

  • 2 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/27/2026HC WainwrightReiterated RatingBuy ➝ Buy
8/6/2026UBS GroupSet Target$14.00
8/6/2026HC WainwrightInitiated CoverageBuy$14.00
8/3/2026Chardan CapitalUpgradeStrong-Buy
7/20/2026Needham & Company LLCBoost TargetBuy ➝ Buy$11.00 ➝ $18.00
7/8/2026Cantor FitzgeraldInitiated CoverageOverweight$17.00
7/8/2026Cantor FitzgeraldInitiated CoverageOverweight$17.00
7/8/2026Cantor FitzgeraldInitiated CoverageOverweight$17.00
6/24/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
6/1/2026OppenheimerReiterated RatingOutperform ➝ Outperform
5/19/2026Chardan CapitalReiterated RatingBuy ➝ Buy$20.00
3/27/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
3/9/2026Needham & Company LLCReiterated RatingBuy ➝ Buy$11.00
12/29/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/22/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/15/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/24/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/13/2025Chardan CapitalReiterated RatingBuy ➝ Buy$20.00
10/31/2025Leerink PartnersUpgradeStrong-Buy
10/31/2025Leerink PartnersInitiated CoverageOutperform$15.00
10/29/2025MizuhoSet Target$12.00
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/30/2025HC WainwrightReiterated RatingBuy ➝ Buy$11.00
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/26/2025Chardan CapitalBoost TargetBuy ➝ Buy$13.00 ➝ $20.00
9/25/2025OppenheimerBoost TargetOutperform ➝ Outperform$21.00 ➝ $30.00
9/15/2025Needham & Company LLCBoost TargetBuy ➝ Buy$8.00 ➝ $11.00
8/26/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$8.00
8/14/2025Chardan CapitalReiterated RatingBuy ➝ Buy$13.00
6/18/2025MizuhoBoost TargetOutperform ➝ Outperform$8.00 ➝ $10.00
6/18/2025Chardan CapitalReiterated RatingBuy ➝ Buy$13.00
6/18/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$9.00
6/5/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$9.00
5/7/2025OppenheimerLower TargetOutperform ➝ Outperform$25.00 ➝ $21.00
5/6/2025Chardan CapitalReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
4/10/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
3/24/2025Chardan CapitalReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
3/21/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
2/6/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
1/13/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
1/8/2025Chardan CapitalReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
1/7/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
12/13/2024Morgan StanleyDowngradeEqual Weight ➝ Underweight
11/20/2024Chardan CapitalReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
11/14/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
9/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
8/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
8/7/2024Chardan CapitalLower TargetBuy ➝ Buy$16.00 ➝ $12.00
5/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$15.00
4/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$15.00
4/2/2024MizuhoLower TargetBuy ➝ Buy$20.00 ➝ $8.00
3/15/2024Chardan CapitalLower TargetBuy ➝ Buy$21.00 ➝ $16.00
3/15/2024Needham & Company LLCLower TargetBuy ➝ Buy$20.00 ➝ $15.00
3/15/2024TD CowenReiterated RatingOutperform ➝ Market Perform
3/15/2024Jefferies Financial GroupReiterated RatingBuy ➝ Hold$16.00 ➝ $3.00
3/14/2024GuggenheimReiterated RatingBuy ➝ Neutral
3/5/2024OppenheimerReiterated RatingOutperform ➝ Outperform$25.00
3/4/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$20.00
2/1/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$20.00
12/1/2023Needham & Company LLCInitiated CoverageBuy$20.00
8/8/2023OppenheimerReiterated RatingOutperform ➝ Outperform$25.00
8/7/2023Chardan CapitalReiterated RatingBuy ➝ Buy$22.00
8/4/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$14.00
4/19/2023MizuhoUpgradeNeutral ➝ Buy$10.00 ➝ $20.00
4/19/2023Morgan StanleyUpgradeUnderweight ➝ Equal Weight$5.00 ➝ $14.00
4/18/2023Chardan CapitalBoost TargetBuy$18.00 ➝ $22.00
3/29/2023MizuhoInitiated CoverageNeutral$10.00
3/7/2023Chardan CapitalReiterated RatingBuy$18.00
2/3/2023Morgan StanleyDowngradeEqual Weight ➝ Underweight$12.00 ➝ $5.00
7/15/2022Morgan StanleyLower TargetEqual Weight$18.00 ➝ $12.00
7/8/2022Chardan CapitalInitiated CoverageBuy$18.00
3/31/2022OppenheimerInitiated CoverageOutperform$25.00
1/7/2022Piper SandlerInitiated CoverageOverweight$41.00
1/3/2022GuggenheimLower Target$42.00 ➝ $30.00
12/30/2021Jefferies Financial GroupReiterated RatingBuy$35.00
(Data available from 9/16/2021 forward)

News Sentiment Rating

-0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2026
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2026
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
6/17/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/17/2026
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/16/2026
  • 2 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 4 very negative mentions
Mentions as of
9/15/2026

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Immuneering logo
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $4.44
Low: $4.24
High: $4.48

50 Day Range

MA: $4.78
Low: $4.05
High: $5.53

52 Week Range

Now: $4.44
Low: $3.86
High: $10.08

Volume

862,111 shs

Average Volume

617,846 shs

Market Capitalization

$287.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Immuneering?

The following sell-side analysts have issued research reports on Immuneering in the last twelve months: Cantor Fitzgerald, Chardan Capital, HC Wainwright, Leerink Partners, Mizuho, Needham & Company LLC, Oppenheimer Holdings, Inc., UBS Group AG, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for IMRX.

What is the current price target for Immuneering?

0 Wall Street analysts have set twelve-month price targets for Immuneering in the last year. Their average twelve-month price target is $17.50, suggesting a possible upside of 294.1%. Oppenheimer Holdings, Inc. has the highest price target set, predicting IMRX will reach $30.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $12.00 for Immuneering in the next year.
View the latest price targets for IMRX.

What is the current consensus analyst rating for Immuneering?

Immuneering currently has 1 sell rating, 4 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMRX will outperform the market and that investors should add to their positions of Immuneering.
View the latest ratings for IMRX.

What other companies compete with Immuneering?

Other companies that are similar to Immuneering include MannKind, Monte Rosa Therapeutics, Corvus Pharmaceuticals, Alumis and Jade Biosciences. Learn More about companies similar to Immuneering.

How do I contact Immuneering's investor relations team?

Immuneering's physical mailing address is 245 Main Street, Second Floor, Cambridge, MA, 02142. The company's listed phone number is 617-500-8080 and its investor relations email address is [email protected]. The official website for Immuneering is www.immuneering.com. Learn More about contacing Immuneering investor relations.